A. Tanaka

发表

Quantitative ex vivo and in vitro receptor autoradiography using 11C-labeled ligands and an imaging plate: a study with a dopamine D2-like receptor ligand [11C]nemonapride.

M. Senda, K. Ishiwata, N. Ogi, 1999, Nuclear medicine and biology.

Evaluation of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings.

Y. Maya, Y. Doi, Y. Shirakami, 2015, Nuclear medicine and biology.

Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist

T. Sugimoto, M. Saito, J. Tsukada, 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

PRECLINICAL AND CLINICAL PROPERTIES OF [123I]ABC577: A NOVEL RADIOIODINATED SPECT AGENT FOR IMAGING B-AMYLOID IN THE BRAIN

D. Jennings, J. Seibyl, K. Marek, 2014, Alzheimer's & Dementia.

Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles.

A. Tanaka, H. Takasugi, H. Sakai, 1994, Journal of medicinal chemistry.

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure.

K. Honda, J. Tsukada, W. Uchida, 1999, European journal of pharmacology.

Quantitative evaluation of central-type benzodiazepine receptors with [125I]Iomazenil in experimental epileptogenesis: II. The rat cortical dysplasia model

K. Morimoto, Takako Onishi, A. Tanaka, 2004, Epilepsy Research.

Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs.

T. Takenaka, J. Tsukada, W. Uchida, 1997, European journal of pharmacology.

Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT). Part 1: identification and structure-activity relationships of a novel series of substituted N-alkyl-N-biphenylylmethyl-N'-arylureas.

H. Tanaka, A. Tanaka, H. Takasugi, 1998, Bioorganic & medicinal chemistry.

Effects of YM471, a nonpeptide AVP V1A and V2 receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2001, British journal of pharmacology.

The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor.

J. Seki, K. Yoshida, A. Tanaka, 1993, European journal of pharmacology.

Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist.

J. Tsukada, W. Uchida, A. Tanaka, 2002, European journal of pharmacology.

Pharmacological Profile of YM 087 , A Novel Potent Nonpeptide Vasopressin V 1 A and V 2 Receptor Antagonist , in Vitro and in Vivo

M. Takanashi, J. Tsukada, W. Uchida, 1997 .

Effect of YM471, an orally active non-peptide arginine vasopressin receptor antagonist, on human vascular smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2002, Journal of hypertension.

Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2000, British journal of pharmacology.

Alterations of Renal Vasopressin V1A and V2 Receptors in Spontaneously Hypertensive Rats

J. Tsukada, W. Uchida, A. Tanaka, 2003, Pharmacology.

Characterization of rodent liver and kidney AVP receptors: pharmacologic evidence for species differences

J. Tsukada, W. Uchida, A. Tanaka, 1999, Regulatory Peptides.

Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells

T. Sugimoto, M. Saito, J. Tsukada, 1998, British journal of pharmacology.

Characterization of vasopressin receptor in rat lung

J. Tsukada, W. Uchida, A. Tanaka, 1998, Neuropeptides.

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.

J. Tsukada, W. Uchida, A. Tanaka, 1998, Cardiovascular research.

Binding Characteristics of YM087, an AVP Receptor Antagonist, in Rhesus Monkey Liver and Kidney Membranes

J. Tsukada, W. Uchida, A. Tanaka, 1998, Peptides.

Comparison of vasopressin binding sites in human uterine and vascular smooth muscle cells.

J. Tsukada, W. Uchida, A. Tanaka, 1999, European journal of pharmacology.

AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1A or V1B receptors

T. Sugimoto, M. Saito, J. Tsukada, 1999, Pflügers Archiv.

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells.

J. Tsukada, W. Uchida, A. Tanaka, 1997, Journal of cardiovascular pharmacology.

Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats.

A. Tanaka, T. Yatsu, M. Aoki, 2005, European journal of pharmacology.

Ethenesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists.

A. Fujimori, K. Sudoh, J. Kazami, 2001, Chemical & pharmaceutical bulletin.

Transport of D‐glucose across cultured stratified cell layer of human oral mucosal cells

H. Yamano, T. Matsumura, M. Ueda, 2002, The Journal of pharmacy and pharmacology.

Renal effect of YM435, a new dopamine D1 receptor agonist, in anesthetized dogs.

Y. Arai, T. Takenaka, K. Honda, 1997, European journal of pharmacology.

Synthesis and pharmacological evaluation of 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline derivatives as specific bradycardic agents.

Toshihiro Watanabe, N. Masuda, A. Kakefuda, 2003, Chemical & pharmaceutical bulletin.

Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.

M. Takanashi, J. Tsukada, W. Uchida, 1997, The Journal of pharmacology and experimental therapeutics.

Highly potent and orally active non-peptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-y l)carbonyl]-2-phenylbenzanilide derivatives.

A. Tanaka, Y. Shimada, T. Yatsu, 2000, Chemical & pharmaceutical bulletin.

Synthesis and biological evaluation of phenylacetyl derivatives having low central nervous system permeability as potent and selective M2 muscarinic receptor antagonists.

A. Kakefuda, A. Tanaka, H. Shibata, 1998, Chemical & pharmaceutical bulletin.

Studies on anti-platelet agents. IV. A series of 2-substituted 4,5-bis(4-methoxyphenyl)pyrimidines as novel anti-platelet agents.

A. Tanaka, H. Takasugi, Y. Motoyama, 1994, Chemical & pharmaceutical bulletin.

Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl) benzanilide derivatives.

H. Koshio, A. Tanaka, T. Yatsu, 1997, Chemical & pharmaceutical bulletin.

Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.

H. Koshio, A. Tanaka, T. Yatsu, 2000, Chemical & pharmaceutical bulletin.

A new synthetic route to YM087, an arginine vasopressin antagonist

T. Mase, S. Sakamoto, A. Tanaka, 2004 .

Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2002, Peptides.

4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. II. Their renal vasodilation activity and structure-activity relationship.

M. Yokota, A. Tanaka, T. Yatsu, 1996, Chemical & pharmaceutical bulletin.

Synthesis and structure-activity relationships in a series of ethenesulfonamide derivatives, a novel class of endothelin receptor antagonists.

A. Fujimori, K. Sudoh, J. Kazami, 2001, Chemical & pharmaceutical bulletin.

Inhibitors of acyl-CoA:cholesterol O-acyltransferase. 2. Identification and structure-activity relationships of a novel series of N-alkyl-N-(heteroaryl-substituted benzyl)-N'-arylureas.

H. Tanaka, A. Tanaka, H. Takasugi, 1998, Journal of medicinal chemistry.

A new radiopharmaceutical: 99mTc DMP for renal scanning

T. Machida, A. Tanaka, M. Miki, 2004, European Journal of Nuclear Medicine.

Synthesis, X-ray crystal structure, and biological activity of FR186054, a novel, potent, orally active inhibitor of acyl-CoA:cholesterol O-acyltransferase (ACAT) bearing a pyrazole ring.

T. Kinoshita, H. Tanaka, A. Tanaka, 1998, Bioorganic & medicinal chemistry letters.

Radiosynthesis, rodent biodistribution, and metabolism of 1-deoxy-1-[18F]fluoro-D-fructose.

Y. Kanazawa, T. Haradahira, M. Maeda, 1995, Nuclear medicine and biology.

Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells.

M. Saito, J. Tsukada, W. Uchida, 1999, European journal of pharmacology.

Preclinical properties and human in vivo assessment of 123 I-ABC577 as a novel SPECT agent for imaging amyloid-β

D. Jennings, J. Seibyl, K. Marek, 2015, Brain : a journal of neurology.

Synthesis, resolution, and renal vasodilation activity of novel DA1 agonists: 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives.

T. Furuya, K. Honda, M. Yokota, 1991, Chemical & pharmaceutical bulletin.

Quantitative evaluation of central-type benzodiazepine receptors with [125I] Iomazenil in experimental epileptogenesis I. The rat kainate model of temporal lobe epilepsy

M. Kakumoto, K. Morimoto, A. Tanaka, 2004, Epilepsy Research.

Ethenesulfonamide and ethanesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists.

A. Fujimori, K. Sudoh, M. Orita, 2001, Bioorganic & medicinal chemistry.

A novel and useful descriptor for hydrophobicity, partition coefficient micellar-water, and its application to a QSAR study of antiplatelet agents.

I. Nakanishi, K. Nakamura, K Nakamura, 1994, Journal of medicinal chemistry.

Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.

M. Orita, J. Tsukada, A. Kakefuda, 2006, Bioorganic & medicinal chemistry.

Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.

J. Tsukada, A. Tanaka, Y. Shimada, 2005, Chemical & pharmaceutical bulletin.

Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1A receptor by introduction of alkoxy groups.

A. Tanaka, Y. Shimada, A. Tahara, 2003, Chemical & pharmaceutical bulletin.

H. Koshio, A. Tanaka, T. Yatsu, 1997, Chemical & pharmaceutical bulletin.

Hemodynamic characterization of YM435, a novel dopamine DA1 receptor agonist, in anesthetized dogs.

T. Takenaka, A. Tanaka, K. Honda, 1997, Journal of cardiovascular pharmacology.